Improving the Effect of Multiple Sclerosis Drugs by Chronobiology - Trial NCT06385197
Access comprehensive clinical trial information for NCT06385197 through Pure Global AI's free database. This phase not specified trial is sponsored by Hadassah Medical Organization and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hadassah Medical Organization
Timeline & Enrollment
N/A
May 08, 2022
Jun 02, 2023
Primary Outcome
safety assessment,assessment of AE,assessment of AE
Summary
A trial for evaluating the ability to improve the effect of dimethyl fumarate in patients
 with Multiple Sclerosis (MS) by chronobiology A controlled-randomization dosing regimen
 administered to patients with MS and provided by a designated app. The treatment limitations
 of time interval is pre-defined according to approved therapeutic windows.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06385197
Device Trial